Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Synthetic octapeptide marketed as a topical anti-wrinkle ingredient (Centerchem/Lipotec). Structurally related to Argireline (Acetyl Hexapeptide-3) but with two additional C-terminal amino acids. Manufacturer marketing positions SNAP-8 as an 'improved' Argireline variant.
Researched for
Reduction of expression wrinkles (topical cosmetics)Modulation of SNAP-25-mediated acetylcholine release in vitro
Official status
US: Unapproved
No FDA medicines approval. Marketable as a cosmetic ingredient.
SNAP-8 is an octapeptide variant of Argireline. The sequence corresponds to the N-terminus of the SNAP-25 protein. As with Argireline, the postulated mechanism is competitive inhibition of the SNARE complex needed for acetylcholine vesicle fusion at the neuromuscular endplate. According to the manufacturer the two extra C-terminal amino acids increase SNARE-complex affinity — there are individual industry studies on this but no independent systematic confirmation.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
3 observations · 2 tiers
Human trial
1
In vitro
2
03
What the studies show
Human trial
Mensch
Visual reduction of expression wrinkles documented in manufacturer-sponsored studies on various skin areas
What does NOT follow: Industry-study effects are typically small and often within the range of high-quality moisturisers. Independent replication in larger cohorts is limited.
In vitro
Zellfreies System
In-vitro SNARE-complex affinity reported as higher than Argireline by manufacturer research
What does NOT follow: Comparison data predominantly from Lipotec's own studies. An independent head-to-head skin-effect study of Argireline vs SNAP-8 is not established.
In vitro
Franz-Zell ex-vivo
Low skin permeation documented in Franz-cell studies — similar to Argireline
What does NOT follow: Permeation is strongly formulation-dependent; reaching relevant concentrations at the dermal site of action remains unclear.
05
Pharmacokinetics
No robust pharmacokinetic human data available. A model curve is not invented.
06
Routes of administration in the literature
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Topical
Used exclusively topically in vehicles with penetration enhancers.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human trial
Skin irritation
Mild, transient local reactions documented in cosmetic studies.
selten
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
08
Risks & hygiene aspects in the literature
What regulatory and scientific literature reports on risks, sterility and identity in non-pharmaceutical sources — descriptive, not a hygiene guide.
Marketing comparison with Argireline
Manufacturer claims that SNAP-8 is stronger than Argireline rely on internal comparison data without independent replication. In practical cosmetic assessment the effect sizes of both substances are small.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
In beauty communities SNAP-8 is often described as a 'stronger Argireline alternative'.
common, primarily manufacturer-driven
Not supported by studies: This claim is not supported by independent comparison studies. Both substances share the same mechanistic approach and the same fundamental permeation problem. Marketing superiority is not clinical superiority.
11
Legal status by country
Country
Status
Note
Checked
EU
Unapproved
EU CosIng-listed as a cosmetic ingredient (INCI: Acetyl Octapeptide-3). Not approved as a medicine.
2026-05-22
United States
Unapproved
No FDA medicines approval. Marketable as a cosmetic ingredient.
2026-05-22
Germany
Unapproved
Follows EU cosmetic regulation.
2026-05-22
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.